| Industry | Estimated fit |
|---|---|
| Healthcare & BiotechMatches your industry (clinical) | 72 |
| Education & TrainingMatches your industry (stem) | 66 |
| Agriculture & FarmingLimit: Not clearly about your industry or what you need funding for; check the… | 54 |
| Arts & CultureLimit: Not clearly about your industry or what you need funding for; check the… | 54 |
| Energy & Clean TechLimit: Nothing in this notice points to energy & clean tech | 54 |
| Environment & ConservationLimit: Nothing in this notice points to environment & conservation | 54 |
| Industry | Estimated fit |
|---|---|
| Food & BeverageLimit: Nothing in this notice points to food & beverage | 54 |
| Housing & Real EstateLimit: Not clearly about your industry or what you need funding for; check the… | 54 |
| ManufacturingLimit: Nothing in this notice points to manufacturing | 54 |
| Social Services & NonprofitLimit: Nothing in this notice points to social services & nonprofit | 54 |
| Technology & SoftwareLimit: Nothing in this notice points to technology & software | 54 |
| Finance & BankingLimit: Nothing in this notice points to finance & banking | 52 |
| Construction & InfrastructureLimit: Nothing in this notice points to construction & infrastructure | 50 |
| Retail & E-CommerceLimit: Nothing in this notice points to retail & e-commerce | 49 |
| Transportation & LogisticsLimit: Nothing in this notice points to transportation & logistics | 49 |
These are our matcher’s estimates for a typical business in each industry. A real match depends on your size, your state and what you need the money for — check your own fit.
NCI R01 awards (~$700,000) to critically and systematically evaluate scientific evidence on carcinogenic hazards to humans, supporting cancer research and prevention. Eligible applicants include universities, nonprofits, state/local/tribal governments, housing authorities, and for-profit organizations including small businesses.
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute invites applications to the Carcinogen Hazard Assessment Monographs Program (CHAMP) Initiative . NCI seeks meritorious proposals to critically and systematically evaluate the scientific evidence on carcinogenic hazards to humans. Identifying potential carcinogens is essential for guiding and advancing cancer research, as well as informing cancer control and prevention efforts.
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Topics
Open opportunities funding similar work, from the same funder or in the same place.
NIH BRAIN Initiative grants to develop tools and computational models for high-resolution, synchronous measurement of complex behaviors alongside neural activity in humans and other species. Eligible applicants include…
NIH/NCI K99/R00 career-development award for early-stage postdoctoral researchers (with research or clinical doctorates) transitioning to independent tenure-track faculty positions; requires the candidate to lead an…
NIH/NCI UH3 cooperative agreement to clinically validate established molecular, cellular, or imaging biomarker assays for cancer detection, diagnosis, prognosis, monitoring, or treatment response using specimens from…
NIH/NCI K99/R00 award for early-stage postdoctoral researchers (with research or clinical doctorates) transitioning to independent faculty careers. The applicant is typically the sponsoring institution; eligible…
NIH/NCI cooperative agreement (UH2/UH3) funding validation of molecular, cellular, and imaging biomarker assays for cancer detection, diagnosis, prognosis, monitoring, and treatment response. Open to universities,…
NIH/NCI program funding revision applications to adapt and clinically validate molecular, cellular, or imaging biomarker assays for cancer detection, diagnosis, prognosis, monitoring, and treatment response prediction.…